Jacobsen Stein 4
4 · RESMED INC · Filed Feb 17, 2010
Insider Transaction Report
Form 4
RESMED INCRMD
Jacobsen Stein
COO, Europe
Transactions
- Sale
ResMed Common Stock
2010-02-12$55.67/sh−17,500$974,181→ 2,376.063 total - Exercise/Conversion
ResMed Common Stock
2010-02-12$38.50/sh+12,000$462,000→ 14,376.063 total - Sale
ResMed Common Stock
2010-02-12$55.65/sh−12,000$667,771→ 2,376.063 total - Exercise/Conversion
ResMed Common Stock
2010-02-12$31.04/sh+17,500$543,200→ 19,876.063 total - Exercise/Conversion
ResMed Common Stock Options
2010-02-12−12,000→ 0 totalExercise: $38.50From: 2007-02-03Exp: 2016-02-03→ ResMed Common Stock (12,000 underlying) - Exercise/Conversion
ResMed Common Stock Options
2010-02-12−17,500→ 52,500 totalExercise: $31.04From: 2009-11-20Exp: 2015-11-20→ ResMed Common Stock (17,500 underlying)
Footnotes (4)
- [F1]Represents first date options became exercisable.
- [F2]This transaction was executed in multiple trades at prices rangining from $55.56 to $55.74. The price reported reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.
- [F3]This transaction was executed in multiple trades at prices rangining from $55.53 to $55.74. The price reported reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.
- [F4]Previous reports aggregated all beneficially owned derivative securities following the reported transaction. This report includes only beneficially owned derivative securities of the same class as those disposed of in this trade, meaning those that have the same grant date and exercise price.